Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dulanermin - Shanghai GeBaiDe

Drug Profile

Dulanermin - Shanghai GeBaiDe

Alternative Names: Apo2L/TRAIL - Shanghai GeBaiDe; recombinant human apoptosis-2 ligand - Shanghai Qiaer; Recombinant Human TRAIL/Apo2L - Shanghai GeBaiDe; Rh-Apo2L; TNFSF10

Latest Information Update: 23 Mar 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Qiaer Bio-Technology
  • Developer Shanghai GeBaiDe Biotechnical Co
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 01 Oct 2016 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT03083743)
  • 17 Apr 2016 Biomarkers information updated
  • 11 Feb 2016 No recent reports on development identified - Phase-III for Non-small cell lung cancer (Combination therapy, Late-stage disease, Locally recurrent) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top